Robert S. Wiesenthal - 29 Aug 2025 Form 4 Insider Report for Strata Critical Medical, Inc. (BLDE)

Role
Director
Signature
/s/ Melissa M. Tomkiel, Attorney-in-fact for Robert S. Wiesenthal
Issuer symbol
BLDE
Transactions as of
29 Aug 2025
Net transactions value
$0
Form type
4
Filing time
03 Sep 2025, 20:43:59 UTC
Previous filing
07 Aug 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Robert S. Wiesenthal filed Form 4 for Strata Critical Medical, Inc. (BLDE) on 03 Sep 2025."

Quick Takeaways

  • This page summarizes Robert S. Wiesenthal's Form 4 filing for Strata Critical Medical, Inc. (BLDE).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Filing timestamp: 03 Sep 2025, 20:43.

What Changed

  • Previous filing in this sequence was filed on 07 Aug 2025.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
WIESENTHAL ROBERT S Director C/O STRATA CRITICAL MEDICAL, INC., 31 HUDSON YARDS, 14TH FLOOR, NEW YORK /s/ Melissa M. Tomkiel, Attorney-in-fact for Robert S. Wiesenthal 03 Sep 2025 0001211785

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRTA Class A common stock, $0.0001 par value per share Award $0 +40,607 +0.78% $0.000000 5,275,662 29 Aug 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2026 Annual Meeting of Stockholders.
F2 Effective as of September 2, 2025, the terms of 886,886 unvested RSUs granted to the Reporting Person by the Issuer on November 9, 2022 and originally reported by the Reporting Person in Table I of a Form 4 filed on November 14, 2022 and 33,591 unvested RSUs granted to the Reporting Person by the Issuer on December 16, 2021 and originally reported by the Reporting Person in Table I of a Form 4 on December 20, 2021, were amended by the Issuer's board of directors to make them subject to an additional performance-related vesting condition. As a result of such amendment, the shares of the Issuer's common stock underlying such unvested RSUs will no longer be included in the securities beneficially owned by the Reporting Person as reflected in column 5 of Table I. Upon satisfaction of the relevant performance-related vesting condition, the Reporting Person will again report the acquisition of such shares on a Form 4.

Sponsored